Citations

Mayo Clinic

Clear

1908 citation(s) found for "Wu, Henry".

Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Massard, Christophe , Retz, Margitta, Hammerer, Peter, Fong, Peter C.C. , Berry, William R. , Romano, Emanuela, Conter, Henry Jacob , Augustin, Marinela , Wu, Haiyan , Schloss, Charles , Poehlein, Christian , Quevedo, Fernando , Gurney, Howard , Piulats, Josep M. , Joshua, Anthony M. , Linch, Mark David , Kolinsky, Michael Paul , Sridhar, Srikala S , Yu, Evan Yi-Wen

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 170-170

10.1200/jco.2019.37.7_suppl.170 Get It

170 Background: Pembro had antitumor activity as monotherapy in pretreated advanced mCRPC (KEYNOTE-028; KEYNOTE-199). KEYNOTE-365 (NCT02861573) is a phase 1b/2 umbrella study testing combinations in mCRPC; we report early results from cohort B combining pembro + docetaxel in mCRPC. Methods: Pts who failed or became intolerant to ≥4 weeks of abi or enza in the pre-chemotherapy mCRPC state received pembro 200 mg IV with docetaxel 75 mg/m2 IV Q3W plus prednisone 5 mg orally twice daily. Pts also progressed within 6 months prior to screening as determined by either PSA progression or radiologic progression in bone or soft tissue. Response was evaluated by PSA levels Q3W and imaging Q9W for first year and Q12W thereafter. Primary end points: safety and PSA response rate (confirmed PSA decline ≥50%). Key secondary end points: investigator-determined ORR (RECIST v1.1), disease control rate (DCR: CR+PR+SD ≥6 mo), time to PSA progression, rPFS, and OS. Results: 72 pts (median age 68 years; PD-L1+ 29%; visceral disease 36%; measurable disease 50%) initiated pembro + docetaxel. Median (95% CI) follow-up was 10 (8-12) mo. Efficacy is outlined in table below. Treatment-related AEs occurred in 69 (96%) pts; most frequent (≥30%) were alopecia (43%), fatigue (40%), and diarrhea (39%). Grade 3-5 treatment-related AEs occurred in 27 (38%) pts, including 2 deaths due to treatment-related AEs (pneumonitis). Conclusions: Combination of pembro + docetaxel/prednisone has activity in pts with mCRPC previously failing anti-hormonal therapy. Observed safety profile for the combination was consistent with known safety profile of each component. Clinical trial information: NCT02861573. [Table: see text]
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
Pitot, Henry C., Hurwitz, Herbert I. , Zanna, Claudio , Brill, Jeffrey Mark, Vuagniaux, Grégoire, Rouits, Elisabeth , Sorensen, John M., Smith, David C.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2531-2531

10.1200/jco.2015.33.15_suppl.2531 Get It

Imaging in patients with severe mitral annular calcification: insights from a multicentre experience using transatrial balloon-expandable valve replacement
Praz, Fabien , Khalique, Omar , Lee, Raymond , Wu, Isaac Y. , Russell, Hyde M., Wang, Dee Dee , Veeragandham, Ramesh, Islam, Ashequl , Deaton, David W., Eudailey, Kyle W. , Akkoc, Deniz, Kantor, Alex , Wang, Catherine , Tang, Diane, Park, Joongheum S, Leung, Diana, Nazif, Tamim , Vahl, Torsten , Kodali, Susheel , Leon, Martin B. , Takayama, Hiroo , Bapat, Vinayak , Borger, Michael A. , Wang, Dee Dee , Praz, Fabien , Guerrero, Mayra , Kaneko, Tsuyoshi , Tang, Diane C H, Hahn, Rebecca T , George, Isaac , Takayama, Hiroo

European Heart Journal - Cardiovascular Imaging | March 6, 2019 | Volume: 20 | Issue: 12 | Pages: 1395-1406

10.1093/ehjci/jez050 | PMID 31220240 Get It

Abstract Aims To investigate valve sizing and the haemodynamic relevance of the predicted left ventricular outflow tract (LVOT) in patients with mitral annular calcification (MAC) undergoing transatrial transcatheter valve implantation (THV). Methods and results In total, 21 patients undergoing transatrial THV, multiplanar reconstruction (MPR), maximum intensity projection (MIP), and cubic spline interpolation (CSI) were compared for MA sizing during diastole. In addition, predicted neo-LVOT areas were measured in 18 patients and correlated with the post-procedural haemodynamic dimensions. The procedure was successful in all patients (100%). Concomitant aortic valve replacement was performed in eight patients (43%) (AVR group). Sizing using MPR and MIP yielded comparable results in terms of area, perimeter, and diameter, whereas the dimensions obtained with CSI were systematically smaller. The simulated mean systolic neo-LVOT area was 133.4 ± 64.2 mm2 with an anticipated relative LVOT area reduction (neo-LVOT area/LVOT area × 100) of 59.3 ± 14.7%. The systolic relative LVOT area reduction, but not the absolute neo-LVOT area, was found to predict the peak (r = 0.69; P = 0.002) and mean (r = 0.65; P = 0.004) post-operative aortic gradient in the overall population as well as separately in the AVR (peak: r = 0.91; P = 0.002/mean: r = 0.85; P = 0.002) and no-AVR (peak: r = 0.89; P = 0.003/mean: r = 0.72; P = 0.008) groups. Conclusion In patients with severe MAC undergoing transatrial transcatheter valve implantation, MPR, and MIP yielded comparable annular dimensions, while values obtained with CSI tended to be systematically smaller. Mitral annular area and the average annular diameter appear to be reliable parameters for valve selection. Simulated relative LVOT reduction was found to predict the post-procedural aortic gradients.
Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in‐hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation
Patel, Nileshkumar, Kumar, Varun , Panakos, Andrew, Narayanan, Mahesh Anantha , Bhardwaj, Bhaskar , Arora, Shilpkumar , Deshmukh, Abhishek , Patel, Nileshkumar , Basir, Mir B. , Cohen, Mauricio G. , Kini, Annapoorna , Sharma, Samin K. , Dangas, George , O’Neill, William W. , Alfonso, Carlos E., Patel, Nileshkumar J , Atti, Varunsiri , Kumar, Varun , Anantha Narayanan, Mahesh , Patel, Nish , Basir, Mir B , Cohen, Mauricio G , Kini, Annapoorna S , Sharma, Samin K , Dangas, George

Catheterization and Cardiovascular Interventions | February 21, 2019 | Volume: 94 | Issue: 4 | Pages: 578-587

10.1002/ccd.28138 | PMID 30790415 Get It

AbstractBackgroundPulseless ventricular tachycardia/ventricular fibrillation (VT/VF) is the initial rhythm in a third of in‐hospital cardiac arrest patients. Mechanical circulatory support (MCS) device use remains poorly understood in this population.MethodsWe conducted an observational analysis of temporal trends in the utilization of MCS in VT/VF IHCA between January 2008 and December 2014 utilizing the Nationwide Inpatient Sample (NIS) database. Using multivariable analysis, we assessed factors associated with MCS use and survival to discharge.ResultsAmong 151,628 hospitalizations with VT/VF IHCA, 14,981 (9.9%) received MCS. Intra‐aortic balloon pump (IABP) was the most commonly used MCS (9.1%). From 2008 to 2014, there was significant increase in the utilization of MCS (8.7–11%; ptrend < 0.0001). On multivariable analysis, there was 12‐fold increase and three‐fold increase in the utilization of PVAD and ECMO respectively; however, there was no significant change in the use of IABP. Over the seven‐year sample period, there was significant increase in the overall survival to hospital discharge (35.4–43.5%; ptrend < 0.0001). Survival to hospital discharge increased in both MCS and non‐MCS groups.ConclusionThere was significant increase in utilization of MCS after VT/VF IHCA during the study period. IABP was the most commonly utilized MCS. The survival to hospital discharge increased in the overall study population including both MCS and non‐MCS groups. Future studies are needed to identify patient population most likely to benefit from the use of MCS after VT/VF IHCA.
Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries
Mercado, Catherine E. , Hartsell, William F. , Simone, Charles B. , Vargas, Carlos , Zhu, He J., Larson, Gary, Simone, Charles B , Tsai, Henry K. , Henderson, Randal H. , Zeng, Jing , Hoppe, Bradford S.

Acta Oncologica | February 20, 2019 | Volume: 58 | Issue: 7 | Pages: 1036-1040

10.1080/0284186x.2019.1575981 | PMID 30784340 Get It

The American neurogastroenterology and motility society gastroparesis cardinal symptom index‐daily diary (ANMS GCSI‐DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis
Revicki, Dennis A. , Speck, Rebecca M. , Lavoie, Sara , Puelles, Jorge , Camilleri, Michael , Camilleri, M , Kuo, Braden , Almansa, Cristina , Parkman, Henry P.

Neurogastroenterology & Motility | February 8, 2019 | Volume: 31 | Issue: 4 | Pages: No page available

10.1111/nmo.13553 | PMID 30734412 Get It

AbstractBackgroundThe purpose of this study was to evaluate the measurement properties of the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index‐Daily Diary, a patient‐reported outcome instrument developed to meet US FDA recommendations for a symptom‐based clinical trial endpoint in gastroparesis. The ANMS GCSI‐DD assesses nausea, early satiety, postprandial fullness, and upper abdominal pain on a severity score from none (0) to very severe (4) and number of vomiting episodes during the past 24 hours. The composite score includes the first four symptoms, the core symptom score includes all five symptoms.MethodsSeventy‐one patients diagnosed with idiopathic or diabetic gastroparesis were recruited for a four‐week observational study. Patients completed the ANMS GCSI‐DD at home between Baseline and Week 4. Statistical analyses included confirmatory factor analysis, item response theory analysis, internal consistency, test‐retest reliability, and construct and known‐groups validity.Key ResultsUnidimensionality for the composite and core symptom scores was supported, and items exhibited good fit. Internal consistency (Cronbach's alpha =0.85 and 0.83) and test‐retest reliability were 0.89 and 0.88, for composite and core symptom scores, respectively. Convergent validity was supported by strong correlations with patient‐reported and clinician measures. Baseline and Week 4 scores differed for three measures used to define disease severity status (P < 0.0001), supporting known‐groups validity.Conclusions & InferencesThe ANMS GCSI‐DD has excellent reliability and validity, supporting its use to assess symptom‐based endpoints in gastroparesis clinical studies. Further analyses will be conducted using clinical trial data to ascertain treatment responsiveness and define a responder.
Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review
Kvetan, Vladimír, Farmer, Joseph C. , Sessler, Curtis N., Christman, John W. , D’Agostino, Rhonda, Gregg, Sara, Khan, Roozehra, Kapu, April N. , Masur, Henry , Mehta, Gargi, Moore, Jason E. , Oropello, John M., Price, Kristen , Hite, R. Duncan , Farmer, J Christopher, Diaz-Gomez, Jose, Pastores, Stephen M. , Coopersmith, Craig M , Díaz‐Gómez, José L.

Critical Care Medicine | January 26, 2019 | Volume: 47 | Issue: 4 | Pages: 550-557

10.1097/ccm.0000000000003637 | PMID 30688716 Get It

Objectives: To assess—by literature review and expert consensus—workforce, workload, and burnout considerations among intensivists and advanced practice providers. Design: Data were synthesized from monthly expert consensus and literature review. Setting: Workforce and Workload section workgroup of the Academic Leaders in Critical Care Medicine Task Force. Measurements and Main Results: Multidisciplinary care teams led by intensivists are an essential component of critical care delivery. Advanced practice providers (nurse practitioners and physician assistants) are progressively being integrated into ICU practice models. The ever-increasing number of patients with complex, life-threatening diseases, concentration of ICU beds in few centralized hospitals, expansion of specialty ICU services, and desire for 24/7 availability have contributed to growing intensivist staffing concerns. Such staffing challenges may negatively impact practitioner wellness, team perception of care quality, time available for teaching, and length of stay when the patient to intensivist ratio is greater than or equal to 15. Enhanced team communication and reduction of practice variation are important factors for improved patient outcomes. A diverse workforce adds value and enrichment to the overall work environment. Formal succession planning for ICU leaders is crucial to the success of critical care organizations. Implementation of a continuous 24/7 ICU coverage care model in high-acuity, high-volume centers should be based on patient-centered outcomes. High levels of burnout syndrome are common among intensivists. Prospective analyses of interventions to decrease burnout within the ICU setting are limited. However, organizational interventions are felt to be more effective than those directed at individuals. Conclusions: Critical care workforce and staffing models are myriad and based on several factors including local culture and resources, ICU organization, and strategies to reduce burden on the ICU provider workforce. Prospective studies to assess and avoid the burnout syndrome among intensivists and advanced practice providers are needed.
Asthma in the older adult
Nanda, Anil , Baptist, Alan P. , Divekar, Rohit , Parikh, N., Seggev, Joram S., Yusin, Joseph, Nyenhuis, Sharmilee Maria

Journal of Asthma | January 18, 2019 | Volume: 57 | Issue: 3 | Pages: 241-252

10.1080/02770903.2019.1565828 | PMID 30656998 Get It

Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method
Smith, Zachary , Rangarajan, Krishna, Barrow, Jennifer , Carter, Danielle, Falvey, Jennifer , Fester, Keith A. , Guido, M. , Hao, Diana, Ou, Narith N., Pogue, Kristen , MacDonald, Nancy, Barrow, Jennifer, Coons, James C , Dzierba, Amy L. , Guido, Maria R

American Journal of Health-System Pharmacy | January 17, 2019 | Volume: 76 | Issue: 3 | Pages: 153-165

10.1093/ajhp/zxy020 | PMID 30689746 Get It